Jinyu Bio-technology Co., Ltd. (SHA:600201)

Market Cap	12.75B +64.7%
Revenue (ttm)	1.39B +10.5%
Net Income	104.27M +30.5%
EPS	0.09 +27.3%
Shares Out	1.09B
PE Ratio	126.16
Forward PE	48.63
Dividend	0.04 (0.32%)
Ex-Dividend Date	Jun 26, 2025

Volume	31,499,523
Open	12.11
Previous Close	12.11
Day's Range	11.63 - 12.23
52-Week Range	7.12 - 19.00
Beta	0.79
Analysts	Strong Buy
Price Target	17.35 (+48.67%)
Earnings Date	Aug 24, 2026

About Jinyu Bio-technology

Jinyu Bio-technology Co., Ltd. manufacturing and sales of veterinary biological drugs in China. The company operates through three segments, such as veterinary biological products, veterinary chemical drugs, and traditional Chinese veterinary medicines. The company offers various pig vaccines, including combined porcine circovirus type 2 and mycoplasma pneumoniae, classical swine fever, combined transmissible gastroenteritis and porcine epidemic diarrhea, swine influenza bivalent, porcine reproductive and respiratory syndrome, pseudorabies ther...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 1,881
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600201

Financial Performance

In 2025, Jinyu Bio-technology's revenue was 1.40 billion, an increase of 11.23% compared to the previous year's 1.26 billion. Earnings were 100.11 million, a decrease of -8.14%.